Table 2. Secondary outcomes: Dosing, Opioid Use and Dose associated adverse events in the DEX and Non-DEX Groups

Outcome measure	DEX Group (n=39)	No DEX Group (n=39)	p value
DOSING 1. Dexmedetomidine, mcg/kg/hr, mean ±SD	0.36 ± 0.12	––	––
2. Morphine, mcg/kg/hr, mean ±SD	33 ± 18.2	26.7 ± 12.3	0.13
3. Fentanyl, mcg/kg/hr, mean (range)	1.5	1(1-2)	––
4. Duration of infusion, hr, median (IQR)	91.5 (64.25-135.25)	67.25 (44.5-170.5)	0.9
Supplemental opioid dosing, n (%)	35 (90)	35 (90)	1
Morphine	34 (97)	28 (80)	0.13
Fentanyl	1(3)	11 (31.4)	0.28
Duration of supplemental dosing, days, median (IQR)	6 (4-8)	7 (4-10)	0.32
Supplemental doses per patient, n (%)	11.6 (13)	15.8 (18.6)	0.35
Patients requiring withdrawal scoring, n (%)	8 (20)	13 (33)	1
Total opioid dose, mcg/kg, median (IQR)	1155 (450-4665)	1841.25 (1291.5-7442.5)	0.01